Please login to the form below

Not currently logged in
Email:
Password:

Ignyta

This page shows the latest Ignyta news and features for those working in and with pharma, biotech and healthcare.

Loxo, Bayer get FDA okay for biomarker-driven cancer drug

Loxo, Bayer get FDA okay for biomarker-driven cancer drug

year. Roche acquired the drug as part of its $1.7bn acquisition of Ignyta last year.

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Pharma deals in March 2015 Pharma deals in March 2015

    Two days' later Teva acquired four oncology development programmes (the most advanced in phase I/II) from Ignyta for $42m.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics